Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Children's Medical Center, Dallas, Texas 75235, USA.
Med. 2021 Apr 9;2(4):395-410. doi: 10.1016/j.medj.2021.01.002. Epub 2021 Feb 23.
Survival among children with high-risk solid tumors remains poor. Reprogrammed metabolism promotes tumor growth and may contain therapeutic liabilities. Tumor metabolism has been assessed in adults using intra-operative C-glucose infusions. Pediatric tumors differ from adult cancers in their low mutational burden and derivation from embryonic tissues. Here we used C infusions to examine tumor metabolism in children, comparing phenotypes among tumor types and between childhood and adult cancers.
Patients recruited to study NCT03686566 received an intra-operative infusion of [U-C]glucose during tumor resection to evaluate central carbon pathways in the tumor, with concurrent metabolomics to provide a broad overview of metabolism. Differential characteristics were determined using multiple comparison tests and mixed effect analyses.
We studied 23 tumors from 22 patients. All tumors analyzed by [U-C]glucose contained labeling in glycolytic and tricarboxylic acid (TCA) cycle intermediates. Labeling in the TCA cycle indicated activity of pyruvate dehydrogenase (PDH) and pyruvate carboxylase (PC), with PDH predominating. Neuroblastomas had high lactate labeling relative to other childhood cancers and lung cancer, and were distinguished by abundant tyrosine catabolites consistent with catecholamine synthesis.
Intra-operative [UC]glucose infusions are safe and informative in pediatric cancer. Tumors of various histologies use glycolysis and oxidative metabolism, with subtype-selective differences evident from this small cohort. Expanding this cohort may uncover predictive biomarkers and therapeutic targets from tumor metabolism.
N.C.I grants to P.L. (R21CA220090-01A1) and R.J.D. (R35CA22044901); H.H.M.I. funding to R.J.D.; Children's Clinical Research Advisory Committee funding to K.J.
高危实体肿瘤患儿的生存率仍然较低。重编程代谢促进肿瘤生长,并且可能包含治疗上的缺陷。成人肿瘤的代谢已经通过术中 C-葡萄糖输注进行了评估。儿科肿瘤在其低突变负担和源自胚胎组织方面与成人癌症不同。在这里,我们使用 C 输注来检查儿童的肿瘤代谢,比较肿瘤类型之间以及儿童期和成人癌症之间的表型。
招募到研究 NCT03686566 的患者在肿瘤切除过程中接受术中[U-C]葡萄糖输注,以评估肿瘤中的中心碳途径,并进行同时代谢组学以提供对代谢的广泛概述。使用多重比较检验和混合效应分析确定差异特征。
我们研究了 22 名患者的 23 个肿瘤。所有通过[U-C]葡萄糖分析的肿瘤都含有糖酵解和三羧酸(TCA)循环中间产物的标记。TCA 循环中的标记表明丙酮酸脱氢酶(PDH)和丙酮酸羧化酶(PC)的活性,其中 PDH 占主导地位。神经母细胞瘤与其他儿童癌症和肺癌相比具有较高的乳酸标记,并且与儿茶酚胺合成一致的丰富酪氨酸分解产物区分开来。
术中[UC]葡萄糖输注在儿科癌症中是安全且信息丰富的。各种组织学类型的肿瘤都使用糖酵解和氧化代谢,从小队列中可以看出亚型选择性差异。扩大这个队列可能会从肿瘤代谢中发现预测生物标志物和治疗靶点。
N.C.I 授予 P.L.(R21CA220090-01A1)和 R.J.D.(R35CA22044901)的研究资助;H.H.M.I. 为 R.J.D. 提供资金;儿童临床研究咨询委员会为 K.J. 提供资金。